AQST:NSD-Aquestive Therapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 4.41

Change

-0.56 (-11.27)%

Market Cap

USD 0.17B

Volume

2.74M

Average Target Price

USD 17.00 (+285.49%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aquestive Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery in the United States and internationally. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The company's proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation of epinephrine for the treatment of anaphylaxis; and AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly and neuroendocrine tumors. It also develops AQST-119, an oral soluble film formulation of tadalafil for the treatment of erectile dysfunction; and APL-130277, a sublingual film using apomorphine to treat parkinson's disease. Aquestive Therapeutics, Inc. was founded in 2004 and is headquartered in Warren, New Jersey.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-29 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+2.58 (+0.96%)

USD69.73B 33.27 26.59
REGN Regeneron Pharmaceuticals, Inc

+1.69 (+0.30%)

USD60.85B 21.61 16.69
SGEN Seattle Genetics, Inc

+0.45 (+0.24%)

USD33.15B N/A N/A
MRNA Moderna, Inc

-0.03 (-0.04%)

USD27.84B N/A N/A
BGNE BeiGene, Ltd

+0.81 (+0.29%)

USD25.12B N/A N/A
RPRX Royalty Pharma plc

+0.80 (+1.94%)

USD25.02B 34.81 9.50
ALXN Alexion Pharmaceuticals, Inc

-0.84 (-0.74%)

USD24.83B 29.87 27.00
GMAB Genmab A/S

+0.38 (+1.03%)

USD23.71B 25.56 2.87
IMMU Immunomedics, Inc

-0.27 (-0.32%)

USD19.77B N/A N/A
INCY Incyte Corporation

-2.93 (-3.24%)

USD19.76B 47.64 35.20

ETFs Containing AQST

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -24.23% 33% F 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.23% 33% F 32% F
Trailing 12 Months  
Capital Gain 34.45% 58% F 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 34.45% 58% F 75% C
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -10.45% N/A N/A 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.45% N/A N/A 17% F
Risk Return Profile  
Volatility (Standard Deviation) 44.80% N/A N/A 26% F
Risk Adjusted Return -23.33% N/A N/A 23% F
Market Capitalization 0.17B 37% F 38% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -2.78 32% F 68% D+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -3,347.45% 1% F 0% N/A
Return on Invested Capital -94.47% 29% F 10% F
Return on Assets -37.70% 30% F 9% F
Debt to Equity Ratio -985.59% 99% A+ 99% A+
Technical Ratios  
Short Ratio 1.32 74% C 72% C-
Short Percent 7.70% 42% F 29% F
Beta 3.72 1% F 1% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector